Carisma Therapeutics (NASDAQ:CARM) and Astellas Pharma (OTCMKTS:ALPMY) Head-To-Head Contrast

Carisma Therapeutics (NASDAQ:CARM) and Astellas Pharma (OTCMKTS:ALPMY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Carisma Therapeutics and Astellas Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1	0	1	1	2.67
Astellas Pharma	0	2	0	0	2.00

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 1,974.69%. Given Carisma Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Astellas Pharma.

Institutional and Insider Ownership

44.3% of Carisma Therapeutics shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Carisma Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Valuation & Earnings

This table compares Carisma Therapeutics and Astellas Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77 million	0.19	-$60.48 million	$0.73	0.07
Astellas Pharma	$12.56 billion	N/A	$334.93 million	$0.47	28.66

Astellas Pharma has higher revenue and earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Astellas Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Carisma Therapeutics and Astellas Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Astellas Pharma	6.39%	22.21%	9.98%

Summary

Carisma Therapeutics beats Astellas Pharma on 8 of the 14 factors compared between the two stocks.

About Carisma Therapeutics

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.